Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life

References

• Catenacci DV, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev 2005;19:301–319.
   PubMed Web of Science ®Google Scholar
• Raza A, Gezer S, Mundle S, et al Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cell in 50 patients with myelodysplastic syndromes. Blood 1995;86:268–276.
   PubMed Web of Science ®Google Scholar
• Bouscary D, De Vos J, Guesnu M, et al Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997;11:839–845.
   PubMed Web of Science ®Google Scholar
• Mundle S, Venugopal P, Shetty V, et al The relative extent and propensity of CD34+ vs. CD34− cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol 1999;69:152–159.
   PubMed Web of Science ®Google Scholar
• Claessens YE, Bouscary D, Dupont JM, et al In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002;99:1594–1601.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Oliva EN, D'Angelo A, Martino B, Nobile F, Dimitrov BD, Perna A. More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol 2002;14:3182–3184.
   Google Scholar
• Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005;352:536–538.
   PubMed Web of Science ®Google Scholar
• Italian Cooperative Study Group for rHuEPO in myelodyspastic syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low risk myelodysplastic syndromes. Br J Haematol 1998;103:1070–1074.
   PubMed Web of Science ®Google Scholar
• Terpos E, Mougiou A, Kouraklis A, et al; for The Greek MDS Study Group. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002;118:174–180.
   PubMed Web of Science ®Google Scholar
• Ross SD, Allen IE, Probst CA, Sercus B, Crean SM, Ranganathan G. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007;12:1264–1273.
   PubMed Web of Science ®Google Scholar
• Park S, Grabar S, Kelaidi C, et al; for the GFM group (Groupe Francophone des Myélodysplasies). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574–582.
   PubMed Web of Science ®Google Scholar
• Spiriti MA, Latagliata R, Niscola P, et al Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic sindrome. Ann Hematol 2005;84:167–176.
   PubMed Web of Science ®Google Scholar
• Musto P, Lanza F, Balleari E, et al Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204–209.
   PubMed Web of Science ®Google Scholar
• Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005;16:1921–1927.
   PubMed Web of Science ®Google Scholar
• Mannone L, Gardin C, Quarre MC, et al Groupe Francais des Myelodysplasies. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome: results of a phase II study. Br J Haematol 2006;133:513–519.
   PubMed Web of Science ®Google Scholar
• Giraldo P, Nomdedeu B, Loscertales J, et al Aranesp in Myelodysplastic Syndromes (ARM) Study Group. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006;107:2807–2816.
   PubMed Web of Science ®Google Scholar
• Gabrilove J, Paquette R, Lyons RM, et al Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008;142:379–393.
   PubMed Web of Science ®Google Scholar
• Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008;87:527–536.
   PubMed Web of Science ®Google Scholar
• Jädersten M, Malcovati L, Dybedal I, et al Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008;26:3607–3613.
   PubMed Web of Science ®Google Scholar
• Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, et al; GFM group (Groupe Francophone des Myélodysplasies). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574–582.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Sun Z, Miller KB, et al Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009;114:2393–2400.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, et al World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671–3674.
   PubMed Web of Science ®Google Scholar
• Chow SC, Shao J, Wang H. In: Fleiss JL, Levin B, Paik MC, editors. Sample size calculations in clinical research. Statistical methods for rates and proportions. 3rd ed. New York: John Wiley & Sons; 2003.
   Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.
   PubMed Web of Science ®Google Scholar
• Marsh JCW, Ganser A, Stadler M. Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol 2007;44:138–147.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, et al Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914–924.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration, Center for Drug Evaluation and Research. Information for healthcare professionals. Erythropoiesis stimulating agents (ESP). Online posting 11 August 2007. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE200711HCP.htm
   Google Scholar